113 results
8-K
EX-10.1
INM
InMed Pharmaceuticals Inc
9 Feb 24
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
12:34pm
all biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety, manufacturing and quality control
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
16 Jan 24
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
2:12pm
completed a Phase 2 clinical trial of INM-755, studying its safety and efficacy in the treatment of symptoms related to Epidermolysis Bullosa (“EB
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
29 Nov 23
Regulation FD Disclosure
2:50pm
studying the safety and efficacy of INM-755 cream for epidermolysis bullosa and preclinical programs in ocular and neurodegenerative diseases.
About Dr
8-K
EX-99.1
f9fbu
14 Nov 23
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update
4:36pm
8-K
EX-99.1
cxxf9raemxw3gbkbvi62
2 Nov 23
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
2:56pm
8-K
EX-10.1
8q61mqu
27 Oct 23
Entry into a Material Definitive Agreement
7:16pm
8-K
EX-99.1
gy69va1
29 Sep 23
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
5:18pm
8-K
m0wi05g3
22 Jun 23
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa
4:28pm
8-K
EX-99.1
ix62nov710dge7lnw4
22 Jun 23
InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa
4:28pm
8-K
EX-99.1
qt3qft8xh9ntr84cy
16 May 23
InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
1:47pm
8-K
EX-10.2
v6ibg4kcqfh8
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
3:47pm
8-K
EX-10.1
i703bo
21 Nov 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
7:02pm
8-K
EX-99.1
8qka95pd4ac6zll1d
17 Nov 22
Regulation FD Disclosure
10:24am
8-K
EX-99.1
diikt h04
14 Nov 22
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
5:44pm